Purchase Short-Term Access
Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection: A Randomized Trial
Dick Menzies, MD, MSc; Richard Long, MD; Anete Trajman, MD, PhD; Marie-JoseĢe Dion, MSc; Jae Yang, MD; Hamdan Al Jahdali, MD; Ziad Memish, MD; Kamran Khan, MD, MPH; Michael Gardam, MD; Vernon Hoeppner, MD; Andrea Benedetti, PhD; Kevin Schwartzman, MD, MPH
Annals of Internal Medicine 2008;149:689-697.
doi:10.7326/0003-4819-149-10-200811180-00003
Purchase Online access to this article for 24 hours
